HIV

HHS Pays For PrEP But Who Will Prescribe It?
HHS Pays For PrEP But Who Will Prescribe It?
Forbes
HHS
HIV
PrEP
Ready Set PrEP
Flag link:
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavir
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavir
Pharmaforum
ViiV Healthcare
HIV
fostemsavir
FDA
Flag link:
Activists seek to block a Gilead patent extension on a lucrative HIV drug
Activists seek to block a Gilead patent extension on a lucrative HIV drug
Stat
Gilead Sciences
patents
HIV
activists
TAF
Flag link:
Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst
Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst
Fierce Pharma
Gilead Sciences
HIV
PrEP
Truvada
Descovy
Flag link:
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment
ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment
Pharmaceutical Business Review
HIV
NIH
ViiV Healthcare
HIV-1
drug discovery
Flag link:
Will Its HIV Lineup Save Gilead Sciences?
Will Its HIV Lineup Save Gilead Sciences?
Motley Fool
Gilead Sciences
HIV
Descovy
Biktarvy
Flag link:
HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills
HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills
Stat
Gilead Sciences
HIV
HHS
Truvada
Descovy
Flag link:
FDA Gives Nod for Breakthrough HIV Test
FDA Gives Nod for Breakthrough HIV Test
Medical Devices and Diagnostics Industry
Vela Diagnostics
HIV
diagnostics
FDA
Sentosa SQ HIV Genotyping Assay
Flag link:
NIH, Gates Foundation commit $200M to cure HIV, sickle cell
NIH, Gates Foundation commit $200M to cure HIV, sickle cell
Fierce Biotech
NIH
Gates Foundation
HIV
sickle cell disease
Flag link:
GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
Fierce Pharma
GSK
ViiV Healthcare
Dovato
DTC ads
HIV
Flag link:
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Marketwatch
JNJ
Janssen
tuberculosis
HIV
philanthropy
Flag link:
Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
Endpoints
Gilead Sciences
Descovy
HIV
PrEP
FDA
Truvada
generics
Flag link:
Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech
Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech
Endpoints
GSK
ViiV
Tivicay
HIV
HemoShear
Flag link:
HIV vaccine shows signs of cross-subtype protection
HIV vaccine shows signs of cross-subtype protection
Fierce Biotech
vaccines
HIV
ALVAC‐HIV
Sanofi Pasteur
GSK
JNJ
South Africa
clinical trials
Flag link:
HIV-focused Gilead launches fund, pledges $2M to help transgender people
HIV-focused Gilead launches fund, pledges $2M to help transgender people
Fierce Pharma
Gilead Sciences
HIV
transgender
philanthropy
Flag link:
CRISPR Gene-Editing May Offer Path To Cure For HIV, First Published Report Shows
CRISPR Gene-Editing May Offer Path To Cure For HIV, First Published Report Shows
NPR
HIV
CRISPR
gene editing
Flag link:
GSK's ViiV reports positive data for long-acting two-drug HIV therapy
GSK's ViiV reports positive data for long-acting two-drug HIV therapy
Biopharma Dive
ViiV Healthcare
GSK
HIV
cabotegravir
rilpivirine
Flag link:
Antiretroviral Therapy's Positive Impact On Global Public Health Faces Challenges Moving Forward
Antiretroviral Therapy's Positive Impact On Global Public Health Faces Challenges Moving Forward
Forbes
HIV
Public Health
antiretrovirals
Flag link:
Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Medical Devices and Diagnostics Industry
Roche
viral assays
HIV
HPV
diagnostics
Global Access Program
Flag link:
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
Endpoints
FDA
Gilead Sciences
HIV
Descovy
PrEP
Flag link:

Pages